AACC conference line-up - Avanti Polar Lipids
This article was originally published in Clinica
Executive Summary
US biotechnology company Avanti Polar Lipids has produced a phospholipid-based VDRL antigen for detecting syphilis which it claims is more sensitive than current VDRL antigens. In an independent test of sera from 100 reactive patients, 88% of sera showed higher reactivity with Avanti's antigen than with another commercially available VDRL antigen. The remaining 12% of sera had the same activity with both antigens tested, said the Alabaster, Alabama-based company.